The first of the seminars commemorating the 10th anniversary of Spectronaut will be conducted by Oliver Bernhardt of Biognosys and guest speaker Birgit Schilling, PhD, from the Buck Institute. The second seminar features guest speakers Jesper Olsen, PhD, from the University of Copenhagen and Yansheng Liu, PhD, from the Yale University School of Medicine. Additionally, Biognosys will present three posters highlighting Spectronaut 16's capabilities for conducting direct searchers on complex decentralised information asset data more efficiently, deep-learning-based scoring, and score identifications with low computing time using the DeepXIC (extracted ion chromatograms) neural network via ion chromatograms.

Furthermore, Biognosys will demonstrate the clinical utility for its TrueDiscovery proteomics platform to aid in unbiased biomarker discovery in biofluids through two presentations. The first presentation identifies healthy versus pathological proteomic biomarkers collected from cerebrospinal fluid and plasma that relate to Alzheimer's disease. The second presentation shows the company's ability to identify differentiating biomarkers for Systemic Lupus Erythematosus in plasma samples, through a collaboration with Takeda.

Finally, Biognosys will discuss its identification of kinase inhibitor protein targets across the cyclin-dependent kinase family using its TrueTarget platform in collaboration with AstraZeneca and Pelago Bioscience.

Biognosys launches proteomics platforms for drug R&D
Biognosys has launched an expanded suite of proteomics platforms that provide pharmaceutical and diagnostics customers with biological insights across...